ANUPAM RASAYAN Q2 FY27: SIGNS 6-YEAR US SUPPLY AGREEMENT; ACQUIRES 50.07% STAKE IN BLISS GVS PHARMA, EXPANDS INTO PHARMACEUTICAL FORMULATIONS

• New US Supply Agreement: Signed a six-year long-term supply agreement with a US-based specialty metal manufacturer, marking its entry into the geological resources sector. • Strategic Acquisition: Completed acquisition of a 50.07% controlling stake in Bliss GVS Pharma, strengthening its pharmaceutical business. • Pharmaceutical Expansion: Acquisition adds finished dosage formulation capabilities, enabling expansion across the pharmaceutical value chain. • Global Customer Expansion: Focused on deepening relationships with existing international customers and expanding into new applications and end markets. • Business Diversification: Strengthening capabilities across Pharmaceuticals, Performance Materials and other specialised chemical segments. • Acquisition Synergies: Management expects operational and commercial synergies from integrating Bliss GVS Pharma with its existing businesses. • Manufacturing Strategy: Prioritising optimal utilisation of capital employed and continuous improvement in manufacturing and technological capabilities. • Future Growth Strategy: Building a globally integrated specialty chemicals and pharmaceutical platform through strategic investments, new applications and customer diversification.

BLISS GVS PHARMA LTD.

← Back to feed